What Is a Pre-Revenue Stock? How to Use the Lottery Ticket Bucket

A pre-revenue stock is a company that’s listed on the stock market but basically has no meaningful sales yet. It might be working on a drug, a new kind of battery, quantum chips, or clean energy—but it is still in the research and development phase, not the “selling a lot of stuff” phase.

You often see pre-revenue stocks in biotech, where a company is burning cash to run clinical trials before it ever gets a drug approved. For example, many early-stage biotech names listed on Nasdaq in 2025–2026 are still years away from their first commercial product and report only small collaboration or grant income in their filings, not steady product revenue.^[1]

You also see them in deep tech areas like quantum computing and fusion energy. Several fusion and next‑gen nuclear ventures that went public via SPACs or direct listings over the last few years are still mostly living off investor capital and government contracts, not selling energy to homes.^[1]

The key point: with a pre-revenue stock, you’re not valuing today’s profits, or even today’s sales. You’re valuing a story about the future: “If this works, it could be huge.” That’s very different from buying a mature company that already sells millions of dollars of products every quarter.

Because there is no real revenue yet, traditional metrics like price-to-sales or price-to-earnings (P/E) don’t help you much. You’re mostly judging:

• How big the opportunity could be if it works
• How real the science or technology is
• How long the cash might last before they need more funding

That’s why many investors mentally put these in a separate “lottery ticket” bucket: high risk, potentially high reward, but not something you build the core of your portfolio around.

Let’s ground this in a few real pre‑revenue or near‑pre‑revenue stories that retail investors followed into 2025–2026. These are examples, not recommendations—they simply show what this category looks like.

1. Fusion energy and space-style bets Companies chasing fusion or advanced space tech often have big dreams and tiny revenue. Several fusion ventures that went public in the last few years are still spending heavily on research facilities, magnets, and plasma experiments, while reporting minimal operating revenue in their 2025 annual reports.^[1] The thesis is simple: if they ever crack commercial fusion, the potential market is enormous—but that might be a decade away, and they could need multiple rounds of funding to survive.

2. Early-stage biotech Many biotech firms in 2025–2026 are pre‑commercial: they run expensive Phase 1 or Phase 2 trials, but have no drugs on the market yet. Read a recent quarterly report from a small-cap biotech and you’ll often see a few million dollars or less in collaboration or milestone payments, but tens of millions in research and development expenses.^[1]

A single positive Phase 2 or Phase 3 readout can move these stocks dramatically in a day. A failed trial can cut the price in half—sometimes more. That’s the lottery ticket feel: one success might be worth billions, but the default outcome is often “nothing comes to market.”

3. Deep tech like quantum and advanced chips Quantum computing and some next‑gen semiconductor startups also fit the pre‑revenue mold. Their 2025–2026 investor presentations talk about pilot projects with big customers, but SEC filings still show small revenue and large losses.^[1]

In all these cases, the stock price is mostly driven by milestones and news flow, not by quarterly sales. For a retail investor, that means you’re effectively betting on milestones: clinical data, regulatory approvals, big partnership announcements, or key technical breakthroughs.

If you’ve ever heard someone say, “this one stock could 10x,” they were probably talking about something pre‑revenue or very early-stage.

Here’s why people compare them to lottery tickets:

• Huge upside if it works: If a fusion company manages a practical reactor, or a biotech firm gets a blockbuster drug approved, the value jump can be dramatic. In the past, some tiny biotech names have moved from a few hundred million dollars in market value to several billions after strong late-stage trial results or an FDA approval.
• High chance of failure: On the flip side, many pre-revenue ventures never make it. Trials fail, the science hits a wall, regulators say no, or funding dries up. Over a multi‑year stretch, a lot of these stocks drift down as they issue more shares to stay alive.

What makes them different from a lottery ticket is that you can actually do research. You can:

• Read the latest 10‑K and 10‑Q filings to see how much cash is left and how fast they’re burning it
• Listen to recent earnings calls or investor days to understand the roadmap
• Track upcoming catalysts: clinical readouts, regulatory decisions, or pilot projects

But even with research, the range of outcomes is extreme. That’s why many experienced investors treat pre-revenue stocks as a separate, small bucket of their portfolio. They understand that most individual names might go to zero or close to it—but the one or two that hit could cover the cost of all the losers and then some.

The key is going in with the right mental model: this is not about fine-tuning valuations like you might with a mature consumer company. It’s about asymmetric bets—small stakes where the downside is limited to what you put in, but the upside, if things go right, could be many times that.

Here’s where most people get into trouble: they fall in love with a pre-revenue story and put way too much of their portfolio into it. Then one bad trial or funding setback hits, and it knocks their whole plan off track.

A simple way to avoid that is to cap each pre-revenue position at around 0.5%–1% of your total portfolio.

• If you have a $10,000 portfolio, 1% is $100 per stock.
• If you have $50,000, 1% is $500.
• At 0.5%, you’re talking $50 and $250, respectively.

That kind of sizing does a few important things:

• Protects your downside: If a single pre-revenue stock goes to zero (it happens), you lose at most 0.5%–1% of your total portfolio. Annoying, but not life‑changing.
• Lets you build a basket: Instead of putting 10% into one moonshot, you might spread that 10% across 10–15 different ideas. That way, you don’t need to “pick the winner.” You just need a couple to work really well.
• Keeps emotions in check: With a small dollar amount at risk, you’re less likely to panic‑sell on a red day or double down irresponsibly when you see a spike.

Some investors even go a step further and cap the entire lottery ticket bucket—maybe 5–10% of the whole portfolio, across all pre-revenue names. The other 90–95% is in more established companies, funds, or cash.

The exact numbers are personal. But the mindset is universal: treat pre-revenue stocks as speculative side bets, not the foundation of your future. You’re buying the right to dream big, without betting the house on any single dream.

You can’t remove the risk from pre‑revenue stocks, but you can avoid the most obvious landmines with a quick, repeatable research routine. Think of this as a 30‑minute checklist before you put real money into any “lottery ticket” idea.

1. Check cash and burn rate Go to the company’s investor relations page and open the latest 10‑Q (quarterly) or 10‑K (annual) filing. Look for:

• Cash and short-term investments on the balance sheet
• Net loss and operating cash flow for the last quarter

Roughly divide cash by the last 12 months of cash burn to estimate how many months of runway they have. If it’s less than, say, 12–18 months, expect the company to raise more money—often by issuing new shares, which can dilute existing shareholders.

2. Identify the next big catalyst Skim the “Business” and “Recent Developments” sections, plus any 2025–2026 press releases. Note upcoming events, like:

• Clinical trial readouts (Phase 1, 2, or 3)
• Regulatory decisions (for example, FDA meetings in biotech)
• Pilot project results or key technical milestones in deep tech

If there’s no clear milestone for the next year or two, your capital could just sit there while they slowly burn cash.

3. Understand the story in one sentence Force yourself to write the thesis in plain English: “This company is trying to do X for Y customers, and if it works, it could be worth Z because…” If you can’t write that clearly, you probably don’t understand what you’re buying.

4. Look at the share count and history In the filings, check how many shares are outstanding and whether that number has been climbing quickly. A rising share count tells you the company has been funding itself by issuing stock, which is common for pre-revenue names—but heavy dilution over time makes it harder for remaining shareholders to win big.

Once you’ve done this quick pass, you’ll be in a much better place to decide whether a stock belongs in your 0.5%–1% lottery bucket—or whether it’s just too messy for your taste.

If you like the idea of pre‑revenue stocks but don’t want them to take over your life, it helps to think in terms of a simple, written plan.

Here’s one way a retail investor might set it up:

1. Set a hard cap on the bucket. For example, “My lottery ticket bucket will never be more than 5–10% of my total portfolio.” 2. Limit each position to about 0.5%–1% of the portfolio. That gives you room for a dozen or more ideas without overloading any single one. 3. Define your universe. Maybe you focus on areas you enjoy learning about—biotech, climate tech, quantum, or space. The goal is not to chase every hype wave on social media, but to pick a few themes you’re willing to study over years. 4. Pre‑decide when you’ll re‑evaluate. For example, you might review each name after a major catalyst (trial result, regulatory decision, big partnership) or once a year. If the story is broken—key trial fails, core tech is shelved—you can choose to exit and recycle that small slice of capital into a new idea. 5. Keep records. Write down when you buy, why you bought, and what you were expecting. Later, that note will help you see whether you were roughly right, way off, or just unlucky.

This turns your lottery ticket bucket from “random speculations” into a structured experiment inside your portfolio. You get the fun of hunting for moonshots and following cutting‑edge science, while most of your long‑term wealth still depends on more predictable holdings.

Over a decade, the odds are high that many of your pre‑revenue bets won’t work. But with thoughtful sizing and a basket approach, you only need a small number of winners to justify the whole bucket. The game is to stay in the arena long enough—and with small enough stakes—that you can actually be around if and when one of your tickets finally hits.